SEC 13F Intelligence

Managers / Q1 2023 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
Under review
reported total failed a data-quality check
Positions
75
Filings on Record
27
2019–present window
Filed
May 15, 2023
original filing

Summary

Compared with Q4 2022, the fund opened 8 new positions and exited 4.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2.2BQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 79.8%Other: 14.6%ADR: 5.6%Equity WRT: 0.0%
  • Common Stock · 79.8% · $1.6B
  • Other · 14.6% · $297M
  • ADR · 5.6% · $114M
  • Equity WRT · 0.0% · $36,000

Quarter-over-Quarter Changes full breakdown →

vs Q4 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SRPTSarepta Therapeutics IncNEW+775.0K775.0K+$107M$107M
Seagen IncNEW+200.0K200.0K+$40M$40M
ELVNEnliven Therapeutics IncNEW+710.6K710.6K+$16M$16M
Kalvista Pharmaceuticals IncNEW+1.65M1.65M+$13M$13M
Morphic Hldg IncNEW+200.0K200.0K+$8M$8M
Rapt Therapeutics IncNEW+300.0K300.0K+$6M$6M
OBIOOrchestra Biomed Hldgs IncNEW+250.0K250.0K+$5M$5M
PRLDPrelude Therapeutics IncNEW+699.0K699.0K+$4M$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2023

75 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1Prometheus Biosciences IncCOM10.00%$204M1.90M
2Reata Pharmaceuticals IncCL A5.49%$112M1.23M
3ONCBeiGene Ltdhistory →SPONSORED ADR5.29%$108M500.0K
4SRPTSarepta Therapeutics Inchistory →COM5.25%$107M775.0K
5Apellis Pharmaceuticals IncCOM5.11%$104M1.58M
6TYRATyra Biosciences Inchistory →COM5.09%$104M6.45M
7RVMDRevolution Medicines Inchistory →COM4.98%$101M4.68M
8Springworks Therapeutics IncCOM4.33%$88M3.42M
9Mirati Therapeutics IncCOM3.65%$74M2.00M
10CYTKCytokinetics Inchistory →COM NEW3.63%$74M2.10M
11AMLXAmylyx Pharmaceuticals Inchistory →COM3.00%$61M2.08M
12Sage Therapeutics IncCOM2.26%$46M1.09M
13Seagen IncCOM1.99%$40M200.0K
14RLAYRelay Therapeutics Inchistory →COM1.76%$36M2.17M
15Merus N VCOM1.72%$35M1.90M
16VKTXViking Therapeutics Inchistory →COM1.64%$33M2.00M
1789Bio IncCOM1.57%$32M2.10M
18AKROAkero Therapeutics Inchistory →COM1.56%$32M831.5K
19NUVLNuvalent Inchistory →COM1.55%$32M1.21M
20IDYAIdeaya Biosciences Inchistory →COM1.49%$30M2.20M
21iTeos Therapeutics IncCOM1.44%$29M2.15M
22Ventyx Biosciences IncCOM1.40%$28M850.0K
23ANABAnaptysBio Inchistory →COM1.39%$28M1.30M
24TNGXTango Therapeutics Inchistory →COM1.38%$28M7.12M
25RCUSArcus Biosciences Inchistory →COM1.28%$26M1.43M
26Amicus Therapeutics IncCOM1.27%$26M2.33M
27RCKTRocket Pharmaceuticals Inchistory →COM1.23%$25M1.47M
28AXSMAxsome Therapeutics Inchistory →COM1.21%$25M400.0K
29BLUBellus Health Inc Newhistory →COM NEW1.13%$23M3.20M
30IOVAIovance Biotherapeutics Inchistory →COM1.11%$23M3.71M
31EXELExelixis Inchistory →COM1.10%$22M1.15M
32XENEXenon Pharmaceuticals Inchistory →COM1.05%$21M600.0K
33Iveric Bio IncCOM0.99%$20M825.0K
34Rain Oncology IncCOM0.92%$19M2.15M
35Point Biopharma Global IncCOM0.89%$18M2.50M
36Avidity Biosciences IncCOM0.85%$17M1.12M
37Day One Biopharmaceuticals ICOM0.78%$16M1.19M
38ELVNEnliven Therapeutics Inchistory →COM0.76%$16M710.6K
39PMVPPMV Pharmaceuticals Inchistory →COM0.74%$15M3.16M
40PRTAProthena Corp PLChistory →SHS0.71%$15M300.0K
41Kalvista Pharmaceuticals IncCOM0.64%$13M1.65M
42CGEMCullinan Oncology Inchistory →COM0.54%$11M1.07M
43NRIXNurix Therapeutics Inchistory →COM0.53%$11M1.22M
44ASNDAscendis Pharma A/Shistory →SPONSORED ADR0.50%$10M95.0K
45Morphic Hldg IncCOM0.37%$8M200.0K
46ORICOric Pharmaceuticals IncCOM0.30%$6M1.05M
47COGTCogent Biosciences IncCOM0.28%$6M525.0K
48Rapt Therapeutics IncCOM0.27%$6M300.0K
49Panacea Acquisition Corp IICL A SHS0.25%$5M500.0K
50OBIOOrchestra Biomed Hldgs IncCOM0.24%$5M250.0K
51Centessa Pharmaceuticals PLCSPONSORED ADS0.24%$5M1.25M
522Seventy Bio IncCOMMON STOCK0.23%$5M459.8K
53Selecta Biosciences IncCOM0.22%$5M3.28M
54CABACabaletta Bio IncCOM0.22%$4M540.0K
55GOSSGossamer Bio IncCOM0.21%$4M3.34M
56PRLDPrelude Therapeutics IncCOM0.20%$4M699.0K
57BDTXBlack Diamond Therapeutics ICOM0.19%$4M2.01M
58Kinnate Biopharma IncCOM0.16%$3M510.0K
59Theseus Pharmaceuticals IncCOM0.15%$3M350.0K
60FATEFate Therapeutics IncCOM0.14%$3M500.0K
61IRONDisc Medicine IncCOM0.14%$3M130.0K
62MISTMilestone Pharmaceuticals InCOM0.14%$3M698.9K
63Atreca IncCL A COM0.12%$3M2.20M
64DBV Technologies S ASPONSORED ADR0.12%$2M1.45M
65Third Harmonic Bio IncCOM0.12%$2M570.4K
66NGM Biopharmaceuticals IncCOM0.10%$2M500.0K
67EQRx IncCOM0.10%$2M1.00M
68BioAtla IncCOM0.09%$2M686.3K
69MREOMereo Biopharma Group PLCSPON ADS0.08%$2M2.25M
70Alaunos Therapeutics IncCOM0.05%$945,0001.50M
71MEI Pharma IncCOM NEW0.03%$667,0002.91M
72TARAProtara Therapeutics IncCOM STK0.03%$655,000209.2K
73Veru IncCOM0.02%$403,000347.3K
74Nuvation Bio Inc*W EXP 07/07/2020.00%$32,000266.7K
75SRZNWSurrozen Inc*W EXP 08/01/2030.00%$4,00066.7K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2.2B79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.